[GIST: adjuvant treatment in Austria].
Adjuvant treatment of gastrointestinal stromal tumor (GIST) patients with Imatinib (400 mg/d) is associated with a statistically significant improvement of relapse-free survival. Risk of relapse has been determined according to Fletcher [8] in the majority of the mentioned trials. However, classification according to Miettinen [9] and Joensuu [10] plus consideration of mutational status might be more accurate. Based upon currently available data, the Austrian GIST-Panel recommends adjuvant treatment with 400 mg Imatinib/day for 1 year for KIT positive GIST patients with a high or moderate risk of relapse (according to Joensuu) [10] following complete resection of the primary tumor.
Brodowicz
Thomas
T
Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien-AKH, Wien, Austria. thomas.brodowicz@meduniwien.ac.at
Kühr
Thomas
T
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D015870:Gene Expression / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D008134:Long-Term Care; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit
Hum Pathol. 2008 Oct;39(10):1411-9
18774375
Br J Cancer. 2007 Jun 4;96(11):1656-8
17533389
Hum Pathol. 2002 May;33(5):459-65
12094370
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78
17090188
Lancet. 2009 Mar 28;373(9669):1097-104
19303137